Compare SHIM & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHIM | PEPG |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.6M | 179.4M |
| IPO Year | 2023 | 2022 |
| Metric | SHIM | PEPG |
|---|---|---|
| Price | $2.44 | $2.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $7.00 | ★ $10.19 |
| AVG Volume (30 Days) | 130.1K | ★ 724.1K |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.95 | 25.61 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $492,844,000.00 | N/A |
| Revenue This Year | $1.41 | N/A |
| Revenue Next Year | $20.36 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.63 | N/A |
| 52 Week Low | $1.95 | $1.31 |
| 52 Week High | $6.76 | $7.80 |
| Indicator | SHIM | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 26.98 | 49.70 |
| Support Level | N/A | $1.60 |
| Resistance Level | $4.09 | $2.62 |
| Average True Range (ATR) | 0.20 | 0.19 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 2.13 | 75.00 |
Shimmick Corp is engaged in delivering turnkey infrastructure solutions that strengthen critical markets across water, energy, climate resiliency, and sustainable transportation. It selectively focuses on the following types of infrastructure projects: Water Treatment, Water Resources, and Other Critical Infrastructure. In water treatment projects the company expands, rehabilitates, upgrades, builds and rebuilds water and wastewater treatment infrastructure. In Other Critical Infrastructure projects, It builds, retrofits, expands, rehabilitates, operates, and maintains critical infrastructure, including mass transit, bridges, and military infrastructure. The company has one operating and reportable segment: infrastructure solutions. All of its revenue is derived from the United States.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.